{
    "clinical_study": {
        "@rank": "104325", 
        "arm_group": [
            {
                "arm_group_label": "CD1579 2.5%", 
                "arm_group_type": "Experimental", 
                "description": "Benzoyl Peroxide 2.5%"
            }, 
            {
                "arm_group_label": "CD1579 5%", 
                "arm_group_type": "Experimental", 
                "description": "Benzoyl Peroxide 5%"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and\n      5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients."
        }, 
        "brief_title": "Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women at the age of 12 or older at the Screening visit.\n\n          -  Those with clinical diagnosis of acne vulgaris with more than 20 noninflammatory\n             lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions\n             (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin).\n\n        Exclusion Criteria:\n\n          -  Those with more than two nodular acne lesions or any cysts.\n\n          -  Those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne,\n             or any drug induced acne.\n\n          -  Those who have clinically significant abnormal findings or conditions on skin other\n             than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially\n             interfere with study assessments according to Investigator's judgment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "234", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073461", 
            "org_study_id": "RDT.07.SPR.27124"
        }, 
        "intervention": [
            {
                "arm_group_label": "CD1579 2.5%", 
                "intervention_name": "CD1579 2.5%", 
                "intervention_type": "Drug", 
                "other_name": "Benzoyl Peroxide 2.5%"
            }, 
            {
                "arm_group_label": "CD1579 5%", 
                "intervention_name": "CD1579  5%", 
                "intervention_type": "Drug", 
                "other_name": "Benzoyl Peroxide 5%"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug", 
                "other_name": "Vehicle"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Benzoyl Peroxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Acne Vulgaris", 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Amagasaki", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Kobe", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Nakano", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Shibuya", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Shinjuku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Galderma investigational site"
                }, 
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Galderma investigational site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-blinded, Vehicle-controlled Parallel Group Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.", 
        "overall_contact": {
            "email": "GaldermaKK.ClinDev@galderma.com", 
            "last_name": "Tetsuya Mita", 
            "phone": "+81-3-5937-3850"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent reduction in total lesion counts", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percent of Subjects With Adverse Events will be evaluated", 
            "safety_issue": "Yes", 
            "time_frame": "up to 12 weeks"
        }, 
        "source": "Galderma R&D", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}